NCT01019694 - Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

470

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Combivent CFC-MDI

36/206 mcg Four times a day (QID)

DRUG

Combivent Respimat 20/100 mcg

Open label randomized parallel

DRUG

Atrovent HFA 42 mcg + Albuterol HFA 200 mcg

Open label randomized parallel

Trial Locations (55)

Unknown

1012.62.153 Boehringer Ingelheim Investigational Site, Jasper

1012.62.145 Boehringer Ingelheim Investigational Site, Mobile

1012.62.156 Boehringer Ingelheim Investigational Site, Mesa

1012.62.135 Boehringer Ingelheim Investigational Site, Berkeley

1012.62.141 Boehringer Ingelheim Investigational Site, Riverside

1012.62.155 Boehringer Ingelheim Investigational Site, Boulder

1012.62.126 Boehringer Ingelheim Investigational Site, Fort Collins

1012.62.131 Boehringer Ingelheim Investigational Site, Wheat Ridge

1012.62.144 Boehringer Ingelheim Investigational Site, Stamford

1012.62.123 Boehringer Ingelheim Investigational Site, Waterbury

1012.62.114 Boehringer Ingelheim Investigational Site, Clearwater

1012.62.124 Boehringer Ingelheim Investigational Site, DeLand

1012.62.139 Boehringer Ingelheim Investigational Site, Pensacola

1012.62.134 Boehringer Ingelheim Investigational Site, Tampa

1012.62.115 Boehringer Ingelheim Investigational Site, Winter Park

1012.62.146 Boehringer Ingelheim Investigational Site, Decatur

1012.62.113 Boehringer Ingelheim Investigational Site, Coeur d'Alene

1012.62.157 Boehringer Ingelheim Investigational Site, Dubuque

1012.62.159 Boehringer Ingelheim Investigational Site, Louisville

1012.62.116 Boehringer Ingelheim Investigational Site, Lafayette

1012.62.148 Boehringer Ingelheim Investigational Site, New Orleans

1012.62.137 Boehringer Ingelheim Investigational Site, North Dartmouth

1012.62.132 Boehringer Ingelheim Investigational Site, Ann Arbor

1012.62.117 Boehringer Ingelheim Investigational Site, Livonia

1012.62.158 Boehringer Ingelheim Investigational Site, Minneapolis

1012.62.127 Boehringer Ingelheim Investigational Site, St Louis

1012.62.129 Boehringer Ingelheim Investigational Site, St Louis

1012.62.147 Boehringer Ingelheim Investigational Site, Cherry Hill

1012.62.149 Boehringer Ingelheim Investigational Site, Summit

1012.62.112 Boehringer Ingelheim Investigational Site, Albuquerque

1012.62.111 Boehringer Ingelheim Investigational Site, Rochester

1012.62.107 Boehringer Ingelheim Investigational Site, Cincinnati

1012.62.120 Boehringer Ingelheim Investigational Site, Cincinnati

1012.62.150 Boehringer Ingelheim Investigational Site, Toledo

1012.62.103 Boehringer Ingelheim Investigational Site, Philadelphia

1012.62.104 Boehringer Ingelheim Investigational Site, Pittsburgh

1012.62.154 Boehringer Ingelheim Investigational Site, East Providence

1012.62.128 Boehringer Ingelheim Investigational Site, Charleston

1012.62.130 Boehringer Ingelheim Investigational Site, Easley

1012.62.151 Boehringer Ingelheim Investigational Site, Greenville

1012.62.161 Boehringer Ingelheim Investigational Site, Greenville

1012.62.109 Boehringer Ingelheim Investigational Site, Greer

1012.62.118 Boehringer Ingelheim Investigational Site, Spartanburg

1012.62.125 Boehringer Ingelheim Investigational Site, Austin

1012.62.140 Boehringer Ingelheim Investigational Site, Fort Worth

1012.62.143 Boehringer Ingelheim Investigational Site, Houston

1012.62.152 Boehringer Ingelheim Investigational Site, Killeen

1012.62.102 Boehringer Ingelheim Investigational Site, San Antonio

1012.62.122 Boehringer Ingelheim Investigational Site, Danville

1012.62.119 Boehringer Ingelheim Investigational Site, Richmond

1012.62.142 Boehringer Ingelheim Investigational Site, Richmond

1012.62.108 Boehringer Ingelheim Investigational Site, Spokane

1012.62.133 Boehringer Ingelheim Investigational Site, Spokane

1012.62.105 Boehringer Ingelheim Investigational Site, Tacoma

1012.62.101 Boehringer Ingelheim Investigational Site, Morgantown